Does urolithin A have anticoagulant effects that increase bleeding risk during surgery or regional anesthesia, and should it be discontinued before procedures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Urolithin A and Perioperative Management

Urolithin A does not require discontinuation before surgery or regional anesthesia, as there is no evidence of anticoagulant effects or increased bleeding risk associated with this supplement.

Evidence Assessment

The FDA drug label for urolithin A 1 contains no warnings about anticoagulant properties, bleeding risk, or perioperative discontinuation requirements. The only contraindication listed is allergy to product components, with general guidance to discontinue if discomfort occurs during use.

Lack of Anticoagulant Properties

Urolithin A is a gut microbial metabolite of ellagic acid that has demonstrated neuroprotective, anti-inflammatory, and autophagy-promoting effects in various disease models 2, 3, 4. None of the available research evidence describes anticoagulant, antiplatelet, or blood-thinning properties. The compound's mechanisms of action involve:

  • AMPK/mTOR/HIF-1α signaling pathway modulation 2
  • AKT-FOXO1-mediated autophagy regulation 3
  • Anti-inflammatory effects through microglial inhibition 4
  • Enhancement of neurogenesis and synaptic plasticity 4

Context: Established Anticoagulant Management

For comparison, established anticoagulants and antiplatelet agents require specific perioperative management:

  • DOACs (apixaban, rivaroxaban, dabigatran): Stop 1-2 days before low-moderate bleeding risk procedures, 2 days before high-risk procedures 5, 6
  • Warfarin: Stop at least 5 days preoperatively 7
  • Aspirin/Clopidogrel: Stop >7-10 days preoperatively 7
  • NSAIDs: Stop 1-10 days depending on specific agent 7

Regional anesthesia guidelines emphasize careful coagulation assessment before neuraxial blockade 8, 9, 6, but these concerns apply to known anticoagulants, not urolithin A.

Clinical Recommendation

Continue urolithin A through the perioperative period without interruption. There is no pharmacological basis for concern about bleeding complications with regional anesthesia or surgery. The supplement does not appear in any perioperative anticoagulation guidelines 8, 10 and lacks the pharmacological properties that would necessitate discontinuation.

If a patient is taking urolithin A alongside actual anticoagulants or antiplatelet agents, manage those medications according to established guidelines while continuing urolithin A without restriction.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.